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ABSTRACT 
Combining cell cycle checkpoint kinase inhibitors with the DNA-damaging 
chemotherapeutic agent gemcitabine offers clinical appeal, with a mechanistic 
rationale based chiefly on abrogation of gemcitabine-induced G2/M checkpoint 
activation. However, evidence supporting this mechanistic rationale from 
chemosensitization studies has not been consistent. Here we report a systematic 
definition of how pancreatic cancer cells harboring mutant p53 respond to this 
combination therapy, by combining mathematical models with large-scale 
quantitative biological analyses of single cells and cell populations. Notably, we 
uncovered a dynamic range of mechanistic effects at different ratios of gemcitabine 
and CHK1 inhibitors. Remarkably, effective synergy was attained even where cells 
exhibited an apparently functional G2/M surveillance mechanism, as exemplified by 
a lack of both overt premature CDK1 activation and S-phase mitotic entry. 
Consistent with these findings, S/G2 duration was extended in treated cells, leading 
to an definable set of lineage-dependent catastrophic fates. At synergistic drug 
concentrations, global replication stress was a distinct indicator of 
chemosensitization as characterized molecularly by an accumulation of S-phase 
cells with high levels of hyperphosphorylated, RPA-loaded single-stranded DNA. In a 
fraction of these cells, persistent genomic damage was observed, including 
chromosomal fragmentation with a loss of centromeric regions that prevented proper 
kinetochore-microtubule attachment. Together, our results suggested a "foot-in-the-
door" mechanism for drug synergy where cells were destroyed not by frank G2/M 
phase abrogation, but rather by initiating a cumulative genotoxicity that deregulated 
DNA synthesis. 
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INTRODUCTION 
The DNA damage response (DDR) to a vast majority of genomic insults is 
orchestrated by the activation of two key phosphatidylinositol 3-kinase-related 
kinases, ATM and ATR. Upon recruitment to damage sites, ATM and ATR 
phosphorylate a number of substrates, including checkpoint kinase CHK1 (CHEK1), 
which in turn mediate cell cycle arrest to facilitate DNA repair (1). An intact 
ATM/ATR-CHK1 signaling cascade is integral to genomic integrity and therefore 
survival. Because cancer cells frequently harbor surveillance defects, they are reliant 
on the residual functional processes of the DDR machinery (2). Inhibition of the DDR 
with checkpoint kinase inhibitors thus heralds a promising cancer therapeutic 
strategy for chemosensitization.  
Early prototypes of non-selective checkpoint kinase inhibitors caffeine and UCN-01 
have been shown to induce unscheduled mitosis following abrogation of DDR-
induced cell cycle arrest (3,4). This has subsequently inspired an accumulating body 
of evidence associating CHK1 inhibition with G2/M checkpoint abrogation, 
characterized by premature chromosomal condensation, inflated mitotic index and 
aberrant chromosomal structures (5-7). Against this background, ongoing clinical 
trials of CHK1 inhibitors with DNA-damaging agents are chiefly based on the notion 
of G2/M checkpoint abrogation (8). Nonetheless, owing to the multiple roles of CHK1 
in cell cycle regulations, it is not definitive if this represents the predominant 
mechanism of chemosensitization (9).  
Among all chemotherapy agents, the greatest potentiation by CHK1 inhibitors has 
been reported with antimetabolites, notably gemcitabine (10). Gemcitabine is 
standard for patients with pancreatic ductal adenocarcinoma, one of the most 
intractable of human malignancies (11). Here, we took a systematic approach to 
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elucidate how pancreatic tumor cells responded to gemcitabine and CHK1 inhibition. 
Using mathematical models coupled with cytotoxicity assays, we first identified 
concentration ratios of gemcitabine and CHK1 inhibitors that induced synergistic 
growth inhibition. We then employed population- and single-cell-based assays to 
quantitatively define cell cycle modulation and cell behaviors. Our study reveals a 
level of mechanistic complexity that offers conceptually important insights into the 
dynamic interplay between gemcitabine and CHK1 inhibition. 
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MATERIALS AND METHODS 
Cell culture and chemicals 
Human pancreatic cancer cells (MIA PaCa-2, Panc-1), colorectal cancer cells (HT-
29) and non-malignant lung fibroblast (IMR-90) were obtained from either the 
European Collection of Cell Cultures or the American Type Culture Collection. They 
were authenticated using either Promega GenePrint10 system or Promega 
PowerPlex 16HS kit, and were grown in DMEM with 10% FBS (GIBCO). Murine 
pancreatic cancer cells K8484 were established from a KRasG12D; p53R172H; Pdx1-
Cre mouse (12) and were grown in DMEM with 5% FBS. All cell lines were grown up 
to a maximum of 20 passages and for fewer than 6 months following resuscitation. 
They were routinely verified to be mycoplasma-free using the Mycoprobe 
Mycoplasma Detection Kit (R&D Systems). Gemcitabine (Tocris), S1181 (Sentinel 
Oncology; patent application: WO/2011/ 141716, compound Example 20), CHIR-124 
(Selleck Chemicals), roscovitine (Sigma-Aldrich), Cdc7i (PHA767491, Tocris) and 
CDK1i (RO3306, Calbiochem) were dissolved in DMSO in aliquots of 10-30mM, kept 
at -20 degree Celsius and used within 3 months. Final DMSO concentrations 
(≤0.2%) were kept constant in all experiments. 
Cell cycle synchronization and flow cytometry 
For G1/S synchronization, thymidine (Sigma-Aldrich) was dissolved in sterile PBS 
and used at a final concentration of 2mM following a 16-hour block/8-hour 
release/16-hour block protocol. For G2/M synchronization, CDK1i (RO3306, 
Calbiochem) was dissolved in DMSO and used at a final concentration of 9uM for 20 
hours. To analyze cell cycle distributions, cells were trypsinized, fixed with either 
70% ethanol or 4% paraformaldehyde, stained with antibodies and counterstained 
with propidium iodide. Samples were analyzed on the BD FACSCalibur flow 
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cytometer (BD Biosciences). ≥10000 events were collected per sample, and data 
were processed using the FlowJo software. 
Clonogenic assay 
Cells were plated 24 hours prior to treatment. Following treatment, equal numbers of 
viable cells from each sample were reseeded in fresh medium and left to grow. 
Seven days later, cells were fixed with 70% methanol and stained with 5% Giemsa 
(Sigma-Aldrich). Colonies were imaged and quantified using the ImageQuant TL 
software (GE Healthcare). Plating efficiency was calculated from the ratio of the 
number of colonies to the number of cells seeded. The number of colonies that arose 
after treatment was expressed as surviving fraction. This was derived from the ratio 
of the number of colonies formed after treatment to the number of cells seeded 
multiplied by plating efficiency of the control. 
Immunostaining and immunoblotting 
For immunostaining, cells were fixed with 4% paraformaldehyde, permeabilized with 
0.3% Triton X-100, stained with antibodies and counterstained with DAPI. To 
visualize centromeres and kinetochores, 100% methanol fixation method was used. 
EdU and TUNEL Click-it assays were performed on paraformaldehyde-fixed samples 
based on Click-it reaction according to manufacturer’s instructions (Life 
Technologies). For immunoblotting, whole-cell extracts were obtained by lysis in 
RIPA buffer (50mM Tris pH8.0, 2mM EDTA, 150mM sodium chloride, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS) and resolved using the SDS-PAGE gel 
system (Life Technologies). Blots were analyzed using the Odyssey Infrared Imaging 
System (LI-COR).  
IncuCyte time-lapse imaging 
7 
 
Images were acquired with the IncuCyte Live Cell Imaging microscopy (Essen 
Bioscience) at every three hours under cell culture conditions with 10X objective. 
Averaged cell confluence was calculated from three random fields of view per well 
using the IncuCyte in-built algorithm. Relative confluence values were obtained by 
normalizing each value to the time zero value in each sample. 
Metaphase spreads 
Cells were treated with 0.1ug/mL colcemid for 45 minutes, trypsinized and treated in 
a drop-wise manner with pre-warmed 0.075M KCl. After 15-minute incubation at 
37°C, cells were sequentially fixed in freshly prepared methanol:acetic acid mix (3:1 
then 3:2). After an overnight incubation at -20°C, cells were dropped onto coverslips 
and stained with ProLong® Gold Antifade Mountant with DAPI (Life Technologies). 
Statistical analyses 
Data were analyzed using the GraphPad Prism built-in tests. For comparison among 
three or more groups, an ordinary one-way ANOVA analysis followed by post hoc 
tests was performed. The following asterisk rating system for p-value was used: 
*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. 
Supplementary Materials and Methods include antibodies; cytotoxicity agent 
combination assay and synergy calculation; acquisition, processing and 
analysis of live-cell time-lapse sequences; and quantitative fluorescence-
based microscopy.  
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RESULTS 
Mathematical modelling identifies effective synergy between gemcitabine and 
CHK1i at sub-GI50 concentrations 
A drug discovery program identified S1181 as a novel selective small molecule 
inhibitor of CHK1 (IC50=2.5nM) (Fig. 1A, Supplementary Fig. S1A, Table S1). Using 
S1181 as a CHK1i tool compound, we performed sulforhodamine B cytotoxicity 
assays to test its effects with gemcitabine on human cancer cell lines (MIA PaCa-2, 
Panc-1, HT-29) and a mouse pancreatic cancer cell line, K8484, obtained from a 
KRasG12D; p53R172H; Pdx1-Cre mouse. To objectively identify the presence and 
region of synergy, we assessed each combination assay independently with three 
established mathematical models, i.e. Bliss, Loewe and Highest Single Agent 
models (see Supplementary Materials and Methods). To further the stringency of our 
criteria, we defined “effective synergy” as the minimum concentrations that produced 
>90% growth inhibition. Consistently, effective synergy was found at sub-GI50 
concentrations in all tumor cell lines but not in non-malignant IMR-90 cells (Fig. 1B, 
Supplementary Fig. S1B).  
Target inhibition occurred at synergistic concentrations, as demonstrated by 
attenuation of CHK1 autophosphorylation at S296 and phosphorylation of ATR 
targets CHK1 S317 and CHK1 S345 (Fig. 1C, Supplementary Fig. S1C) (13). With 
24 hours of combination treatment, ATM S1981 nuclear foci were observed, 
alongside the upregulation of its downstream substrates CHK2 T68 and H2AX S139 
(yH2AX), implying elevated DNA damage that involved fork breakage (Fig. 1C-D). 
With 72 hours of combination treatment, cell viability was severely affected, as 
evidenced by increase in yH2AX, cleaved PARP and caspase-3, apoptotic bodies, 
and TUNEL staining (Supplementary Fig. S1D-F). Long-term clonogenic assays 
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corroborated a durable synergistic relationship between the two agents (Fig. 1E, 
Supplementary Fig. S1G). Together, the data demonstrate that sub-GI50 
concentrations of gemcitabine and CHK1i are sufficient to yield synergistic growth 
inhibition.  
Forced mitotic entry is not a common determinant of effective synergy 
A widely held assumption is that CHK1 inhibition abrogates the G2/M checkpoint by 
triggering inappropriate CDK activation, leading to forced mitotic entry. To test this 
notion in the context of effective synergy, we interrogated CDK activation status (Fig. 
2A). Unexpectedly, we found no apparent disinhibition of CDK activity (i.e. no 
decrease in the inactive form CDK Y15) upon gemcitabine+CHK1i treatment at 
synergistic concentrations. To rule out potential off-target effects of S1181, we used 
another structurally distinct potent CHK1-specific inhibitor CHIR-124 and achieved 
similar outcomes at relevant synergistic concentrations (Supplementary Fig. S2A-B). 
We investigated if these molecular changes were accompanied by forced mitosis. 
Both quantitative immunoblotting and cytometry for mitotic marker HH3 S10 (pHH3) 
confirmed that the synergistic combination did not substantially elevate the mitotic 
population compared to single-agent controls (Fig. 2A, Supplementary Fig. S2C). 
Furthermore, DNA content of the mitotic cells treated with the synergistic 
concentrations was near 4N regardless of treatment duration (24-72 hours), 
suggesting an absence of forced S-phase mitotic entry (Fig. 2B and Supplementary 
Fig. S2D; see data for 10nM gemcitabine+1uM S1181). 
Cancer cells display divergent mechanistic interpretations at different 
concentration ratios 
A potential caveat of the above findings is that they were attained under fixed-ratio of 
gemcitabine and CHK1i, and thus did not capture the dynamic range within which 
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synergy may arise. To address this, we revisited the synergy plots and paired up a 
fixed concentration of CHK1i with low and high gemcitabine (Fig. 2C, Supplementary 
Fig. S2E). CHK1i with low gemcitabine, while synergistic, neither triggered CDK 
inactivation nor substantially altered the percentage of pHH3-positive population 
compared to single-agent control (Fig. 2C, compare lane 3 with lane 5). Conversely, 
with high gemcitabine, there was obvious G2/M checkpoint override exemplified by 
decreased CDK Y15 and elevated pHH3 (Fig. 2C, compare lane 4 with lane 6). 
Quantification of DNA content shows that, independent of treatment duration, pHH3-
positive cells in high gemcitabine were consistently <3N, a signature of premature S-
phase mitotic entry (Fig. 2B, Supplementary Fig. S2D; see data for 100nM 
gemcitabine+1uM S1181).  
We did a reverse set of experiments, where a fixed gemcitabine was coupled with 
increasing CHK1i (Fig. 2D, Supplementary Fig. S2F). With low synergistic CHK1i, we 
did not see gross G2/M checkpoint abrogation as there was little change in the levels 
of CDK Y15 and pHH3. With higher CHK1i, CDK activation (reduced CDK Y15) that 
promoted mitotic entry (elevated pHH3) became more apparent. All these 
experiments were reproducible in cell lines with different synergistic concentrations 
(Fig. 2C-D, Supplementary Fig. S2E-F). To further verify these findings in the same 
setting, we employed yet another cell line HT-29, which has previously been shown 
to undergo unscheduled mitotic entry with CHK1 inhibition (14), and reached the 
same conclusions (Fig. 2E): with low synergistic gemcitabine (30nM) and CHK1i 
(1uM), the percentage of mitotic cells was not considerably different from single-
agent controls and they had ~4N DNA content; with high gemcitabine (300nM) and 
CHK1i (5uM), there was an increase in <4N mitotic cells. Collectively, while our data 
are in line with previous reports on G2/M checkpoint abrogation at relatively high 
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concentrations of gemcitabine or CHK1i, they argue for the hitherto discounted 
possibility that this is dispensable at optimal synergistic ratios of gemcitabine and 
CHK1i. 
Delayed S progression is a denominator of cytotoxicity, regardless of the 
mode of elimination   
The foregoing experiments suggest that forced mitotic entry is inadequate to explain 
the effective synergy between gemcitabine and CHK1i. First, the principle of effective 
checkpoint abrogation would apply if cells experience supra-physiological levels of 
DNA damage in the first instance; such was not the case with sub-GI50 gemcitabine 
alone (Fig. 1, Fig. 2). Second, cells treated with gemcitabine at synergistic 
concentrations in the absence of CHK1i remained cycling for at least 72 hours, 
incongruent with the notion of an alarmed G2/M checkpoint (Supplementary Fig. 
S3A). Third, given the nominal extent of checkpoint activation, checkpoint abrogation 
by CHK1i would be more a conditional than an absolute requirement for synergy, 
explaining the absence of overt perturbation on CDK1 activity (Fig. 2). 
To validate these conclusions, we reasoned that there must be a mechanistic 
underpinning that preceded G2/M checkpoint abrogation. We performed quantitative 
flow cytometry to determine cell cycle profiles. Consistently, gemcitabine+CHK1i at 
synergistic concentrations resulted in an increase in S-phase population (Fig. 3A, 
Supplementary S3B, Table S2). To directly correlate spatiotemporal configuration of 
cell-cycle dynamic with treatment conditions, we harnessed the Fluorescent 
Ubiquitination-based Cell Cycle Indicator (Fucci) technology, which distinguished 
S/G2-M cells from G1 cells based on fluorescently tagged forms of geminin (green) 
and Cdt1 (red), respectively (Supplementary Fig. S3C) (15). In tandem, we 
developed a live-cell tracking methodology that allowed measurement of S/G2 
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duration in an automated and reproducible fashion (see Supplementary Materials 
and Methods). Analyzing over 2000 single cells, we found that the averaged S/G2 
duration in gemcitabine-treated cells (10.4 ± 0.25h) was 2 hours longer than control 
(8.6 ± 0.16h) and CHK1i (8.2 ± 0.16h) (Fig. 3B). Gemcitabine+CHK1i prolonged the 
interphase residence time by another 3 hours (13.3 ± 0.53h), consistent with the 
accumulation of the S-phase population (Fig. 3A). 
Time-lapse analysis showed diverse cell fates following gemcitabine+CHK1i (Fig. 
3C). To facilitate comparative analyses without compromising the complexity, the 
first-generation fate profile of each individual cell from the time of treatment to the 
end of first mitosis (if occurred) was plotted (Fig. 3D). Of the 115 asynchronous cells, 
eighty-three cells proceeded to the next cell cycle while thirty-two cells experienced 
adverse fate in the first observed cell cycle. Among these thirty-two cells, two died in 
mitosis, fifteen failed cytokinesis, while the remaining fifteen experienced prolonged 
arrest (three), senescence (seven) or death (five) in S/G2 interphase without ever 
entering mitosis. Notably, twenty-three out of twenty-nine cells in the fourth quartile 
of S/G2 duration experienced adverse fates. All these data stood in contrast to the 
first-generation fate profiles of the control, where all the 100 cells entered mitosis 
following a relatively short S/G2 duration and successfully underwent cytokinesis 
(Supplementary Fig. S3D). Together, these data support a model where, irrespective 
of how a cell is eliminated, prolonged S duration appears to be a key that presages 
an unfavorable biological event. 
Cell fate is influenced by the extent of agent exposure across generations 
If the above hypothesis is generally applicable, we postulated that there should be a 
lineage-dependent phenomenon where cell fate could be extrapolated from the initial 
state of a cell. To test this, we first performed a pedigree examination 
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(Supplementary Fig. S3E). We tracked cells that underwent one mitotic division in 
order to identify daughter cells derived from the same mother. We then determined 
the fate of 75 pairs of sisters. We found that most sisters shared the same fate upon 
gemcitabine+CHK1i. Based on this and our earlier results, we reasoned that cell fate 
decision could be dependent on the degree of maternal exposure during S/G2. 
Strikingly, we found that offspring of mothers with protracted S/G2 progression were 
more prone to some form of adverse fate (failed cytokinesis, interphase arrest, 
senescence, death) than those with mothers of shorter S/G2 duration (Fig. 3E). 
Furthermore, linearity between the S/G2 duration and mitotic duration implies a 
causal connection between the interphase state and subsequent mitotic state, 
providing an explanation to previous work that implicates CHK1i in activating the 
spindle assembly checkpoint (16). 
Next, we asked if S/G2 duration progressively lengthened through generations. To 
address this in a manner that ensured complete retrieval of temporal data, we 
focused on cells that were in G1 phase at the start of each experiment and that had 
at least one dividing daughter. Significantly, S/G2 duration doubled over two 
generations (Fig. 3F). This was accompanied by a five-fold increase in mitotic 
duration (Supplementary Fig. 3SF). Furthermore, virtually all second-generation cells 
affected by the temporal inflation failed to divide, consistent with the phenomenon 
seen in the first-generation population. As a unifying validation to all our findings, we 
determined the S/G2 and mitotic durations of cells that proceeded into the second 
cell cycle in order to correlate them to their fate. Whereas 72% (83 out of 115 cells) 
underwent division in the first cell cycle, the percentage dropped to 15% (25 out of 
164 cells) in the second round (Supplementary Fig. S3G). Moreover, in daughters 
that attempted a second mitosis, we again saw a positive association between the 
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length of S/G2 and mitosis, with those cells at the higher ends being more vulnerable 
to cytokinesis failure (Supplementary Fig. 3SH). Together, our lineage-tracing 
analyses highlight the effects of agent exposure during interphase and how that 
could propagate across the descendants of an insulted cell. 
CHK1 inhibition triggers global replication stress by deregulating the 
replication checkpoint 
The distinctive phenotype of perturbed S progression prompted us to interrogate the 
intra-S replication activity upon treatment. First, we synchronized MIA PaCa-2 cells 
at the G1/S border and released them into treatment conditions, labelling with EdU 
over 1-4 hours (Fig. 4A). To enumerate the fraction of replicating cells, we employed 
quantitative fluorescence-based microscopy, which enabled the analysis of 
thousands of single-cell measurements based on multiple parameters of the 
fluorescent readout (see Supplementary Materials and Methods). We found that 
CHK1i caused a more rapid initial uptake of EdU in MIA PaCa-2 cells compared to 
control or gemcitabine 2-3 hours following release. When asynchronous populations 
of another cell line HT-29 were treated with CHK1i and then labelled with a shorter 
pulse of EdU, we again observed a significant increase in replicating cells 
(Supplementary Fig. S4A). Collectively, the data suggest enforced initiation and 
promotion of DNA synthesis with CHK1 inhibition. 
Forced DNA synthesis is a source of replication stress (17). In response to 
replication stress, single-stranded DNA (ssDNA)-coating trimeric RPA protein is 
recruited and phosphorylated at multiple sites, with RPA32 S4/8 being found in the 
most hyper-phosphorylated form of the protein (18). We observed an increase in 
phosphorylated RPA upon gemcitabine+CHK1i treatment but not with either agent 
alone (Supplementary Fig. S4B). This exclusivity highlights the dependency between 
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the two agents in deregulating the replication program. Furthermore, quantitative 
microscopy reveals that cells with the highest degree of RPA32 S4/8 were also 
experiencing substantial fork breakage, as evidenced by co-staining with yH2AX 
(Fig. 4B, Supplementary Fig. S4C). The majority of these cells were in S-phase 
(Supplementary Fig. S4D). High-resolution confocal imaging shows nucleus-wide 
staining of activated RPA in these cells, indicative of long stretches of ssDNAs with 
stalled replication forks (Supplementary Fig. S4E). On the other hand, yH2AX was 
found in heterochromatic regions, consistent with the presence of replication 
intermediates refractory to repair (19). Together, the data suggest that 
gemcitabine+CHK1i overloads the replication machinery through improper initiation 
and promotion of DNA synthesis, eventually leading to the pathological outcome of 
unresolved DNA lesions.  
A reverse prediction was that suppression of DNA synthesis should relieve global 
replication stress. To this end, we exploited the paradigm that CHK1 regulates origin 
activity and that origin activity requires CDK2 (20). We found that application of a 
broad CDK inhibitor roscovitine with gemcitabine+CHK1i reversed S-phase 
accumulation within 12 hours (Fig. 4C). By 24 hours, roscovitine markedly subdued 
yH2AX and RPA32 S4/8 expressions in treated cells, indicating mitigation of 
replication stress (Fig. 4D). These results were reproduced by inhibiting Cdc7, 
another regulator of origin firing (Fig. 4C-D).  
Given that inhibition of CDKs and Cdc7 is cytostatic, a counter-argument would be 
that the apparent rescue was an indirect effect of reduced genome incorporation of 
gemcitabine. To address this, we asked whether restraining DNA replication in 
gemcitabine+CHK1i could abolish the synergistic growth inhibition. We performed 
long-term proliferation studies (Fig. 4E, Supplementary Fig. S4F). Significantly, cell 
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proliferation was restored to control levels by roscovitine and Cdc7i, partially or fully 
so depending on cell lines. Substituting roscovitine with a specific CDK1i at sub-
arresting concentrations did not redress growth retardation by gemcitabine+CHK1i 
(Supplementary Fig. S4G). Together, these data show that, at sub-GI50 
concentrations, CHK1i synergizes with gemcitabine mainly by perturbing the S-
phase homeostasis through deregulated DNA replication, not by G2/M checkpoint 
abrogation. 
Mitotic aberrance is a consequence of deranged replication machinery 
Emerging evidence suggests that genomic insults in interphase can persist into 
mitosis (21). Given that a fraction of cells underwent prolonged mitosis upon 
gemcitabine+CHK1i, we proceeded to determine the nuclear morphology of these 
cells. Aberrant mitotic architectures were significantly found in the combination 
treatment (Fig. 5A-B). These included misaligned metaphases, lagging 
chromosomes and anaphase bridges. When cells were synchronized at the G2/M 
border and released into gemcitabine+CHK1i, there was no evidence of gross mitotic 
aberrance (Supplementary Fig. S5A). This ruled out the possibility that CHK1 mitotic 
role was compromised (22). Together, the data suggest that preceding replication 
mishap is responsible for the aberrant mitotic manifestations. 
We noticed that misaligned metaphases with dramatic dispersion of chromosomes 
were particularly common with CHK1 inhibition. Previous studies have invariably 
attributed this feature to checkpoint bypass, but have variously described it as 
disorganized spindle (23), centromere fragmentation (24) and failure of 
chromosomes with intact centromeres to align along the metaphase plate (14). To 
clarify, we stained cells for tubulin and found apparently normal bipolar microtubule 
organization (Fig. 5A). With z-stack confocal analysis, we found core component of 
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kinetochore outer plate HEC1 co-localizing exclusively with chromosomes at the 
metaphase plate (Fig. 5C). This was accompanied by the presence of genome 
material separate from the plate, indicative of acentric chromosomes. Similar spatial 
configuration was also observed with centromere DNA-binding CENP-B. Given that 
(peri)centromeric structures arise from heterochromatin, damage in this region would 
conceivably result in their defective formation. This is consistent with the observation 
that only with CHK1 inhibition (with or without gemcitabine) did yH2AX propagate 
into heterochromatin (Supplementary Fig. S5B). 
An alternative but not mutually exclusive explanation was chromosomal 
fragmentation, a phenomenon increasingly recognized as a form of mitotic death but 
often confused with premature chromosomal condensation (PCC) (25). To formally 
investigate this possibility, we performed immunofluorescence and found that (1) 
yH2AX decorated aberrant mitoses, more so in those with severely tattered 
chromosomes (Fig. 5D), (2) mitoses were EdU-negative and were not actively 
replicating (Fig. 5E), and (3) mitotic aberrance was not abolished by CDK inhibitor 
co-treatment (Supplementary Fig. S5C). Furthermore, independent of combination 
treatment duration (24-72 hours), metaphase spreads showed various stages of 
chromosomal breakage demonstrated by differential cut sizes, suggesting that it was 
a cumulative process that occurred at single-cell level (Fig. 5F). Together, these data 
confirm chromosomal fragmentation, preclude PCC (26) and premise that the 
replication crisis invoked by gemcitabine+CHK1i could progressively culminate in 
mitotic disaster. 
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DISCUSSION 
An overwhelming body of literature proposes that checkpoint abrogation by CHK1i in 
gemcitabine-treated cells drives them into premature mitosis. However, such 
abrogation has never been formally established as the cause of chemosensitization 
(9). Importantly, G2/M checkpoint bypass by CHK1i does not always correlate with 
gemcitabine sensitization (7). Our findings explain some of these apparent 
discrepancies.  
We have demonstrated that the mechanistic properties of effective synergy between 
gemcitabine and CHK1i are in fact consistent but contingent on the degree of 
genotoxicity induced. This in turn is concentration-sensitive. The salient features of 
this modulation are generalized in Fig. 6A. By itself, low yet synergistic 
concentrations of gemcitabine retard DNA synthesis but do not elicit permanent 
proliferation blockade. Thus, delayed but timely mitotic CDK1 activation enables cells 
to cycle into mitosis. This places a limit on the extent of CDK1 disinhibition and 
hence checkpoint abrogation when CHK1 is inhibited. Counterintuitively, at higher 
gemcitabine concentrations (which by themselves are cytotoxic), the same extent of 
CHK1 inhibition triggers unscheduled CDK1 activation and premature S-phase 
mitosis. One scenario explaining this phenomenon is the synchronizing effects of 
high-concentration gemcitabine. At high concentrations, cells are uniformly and often 
irreversibly blocked in S-phase. Addition of CHK1i hence promotes simultaneous 
premature mitosis of these arrested cells, leading to an apparent inflation in CDK1 
activity and mitotic index with <4N state. Virtually all functional studies on CHK1i to 
date that have reported such phenomena base their conclusions on the higher end 
(>GI50) of gemcitabine concentrations, as much as 10-200 times above the 
concentrations where effective synergy is typically observed (7,14,27-29). 
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We have shown that the immediate response of cells upon addition of CHK1i to 
gemcitabine at lower, synergistic concentrations is not premature S-phase mitotic 
entry. Instead, cells experience prolonged interphase with enhanced DNA damage 
and replication stress, reminiscent of the nucleus-wide replication catastrophe when 
ATR signaling is perturbed (30). A fraction of these cells enter mitosis, often with 
disastrous consequences. While this in principle suggests G2 abrogation, given the 
global mitotic CDK1 suppression and substantial delay in mitotic entry as well as the 
low concentrations of the agents used, the data are also compatible with the notion 
of G2 checkpoint adaptation. It has been shown that G2 adaptation can occur in 
human cells and is possible following pharmacological concentrations of genotoxic 
agents (31,32). Taken together, as opposed to blatant checkpoint abrogation, our 
study illustrates a “foot-in-the-door” phenomenon (Fig. 6B). This model proposes that 
premature S-phase mitotic entry is not the predominant route to chemosensitization. 
Instead, CHK1i synergizes with gemcitabine via a more subtle and far-reaching 
mechanism, i.e. first by engaging cells in disorderly replication, then committing them 
to elimination processes that could take place in and beyond mitosis. 
Our mechanistic study raises several key issues regarding the development of 
CHK1i as cancer therapeutics. First, largely based on preclinical studies that have 
used high concentrations of genotoxic agents, emerging consensus on treatment 
regimen advocates a delayed administration of CHK1i (10,33). However, early 
clinical results from UCN-01 trials suggest that delayed administration of the 
checkpoint kinase inhibitor has been suboptimal in chemosensitization, with 
inconsistent evidence of checkpoint bypass. However, it is uncertain if any of the 
enhanced effect seen with a staggered regimen represents true synergy or if it is a 
result of accelerated (but not necessarily synergistic) cytotoxicity. In the most 
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promising clinical trial so far, two patients with  pancreatic adenocarcinoma  
exhibited stable disease lasting > 10 months, and there was a partial response in a 
cholangiocarcinoma  patient,  in a Phase I dose escalation study, when CHK1i MK-
8776 was given only 30 minutes after gemcitabine (34). We have shown with the aid 
of mathematical models that non-cytotoxic concentrations of gemcitabine and CHK1i 
could yield effective synergy in tumor cells when given together. We propose that 
simultaneous administration of both agents warrants further investigation. This is 
especially germane in view of the variable intratumoral gemcitabine levels expected 
in patients, owing to short half-life and poor drug delivery (12). Second, dose-
dependent toxicities are a major cause of drug attrition. Clinical development of 
several checkpoint kinase inhibitors has been discontinued, the most recent being 
AZD7762 given its untoward cardiotoxicity (35). We have shown that a threshold of 
CHK1 inhibition beyond that necessary for synergy is required for overt checkpoint 
abrogation. As our data suggest that inhibition of S-phase activities of CHK1 is more 
relevant to chemosensitization, concurrent administration of gemcitabine and CHK1i 
would in principle obviate the need for G2/M checkpoint abrogation. We anticipate 
that metronomic gemcitabine, where low doses are given at frequent intervals, 
represents an opportunity where the synergistic interaction between the 
antimetabolite and CHK1i could be exploited (36). Third, low doses of gemcitabine 
and CHK1i would permit the possibility of triple drug therapies. This is potentially 
applicable to treatment modalities to which S-phase cells are particularly vulnerable, 
for example radiotherapy. In support of this and the notion that G2/M bypass is 
dispensable for synergy, radiosensitization has been reported to occur most 
optimally when CHK1 is inhibited during S-phase, but not when G2/M abrogation is 
maximal (37). Attractive concepts on chemoradiosensitization with checkpoint kinase 
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inhibitors have been proposed but remain largely unexplored (10). Our data illustrate 
a distinct mechanistic perspective on CHK1 inhibition that serves as a reference for 
future combination and scheduling work. 
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FIGURE LEGENDS 
Figure 1. Sub-GI50 concentrations of gemcitabine and CHK1i yield effective 
synergy. 
(A) Chemical structure of CHK1 inhibitor S1181.  
(B) Cytotoxicity assay. MIA PaCa-2 cells were treated with gemcitabine (x-axis) and 
S1181 (y-axis) in an 8 X 8 concentration checkerboard format for 72 hours. Cell 
viability was determined by measuring the total protein content using the 
sulforhodamine B assays. The experimental data (left, values are percentage growth 
inhibition compared to control) was analyzed independently with the three synergy 
models (Bliss, Loewe, Highest Single Agent). The predicted inhibition data by these 
models (middle) was subtracted from the experimental data (left), yielding a final 
difference value for each combination (right). The greater a difference value was, the 
more synergistic that particular combination was. Concentrations that yielded 
effective synergy (as defined in the text) are boxed in white in Data-Prediction panel. 
Data are represented as mean ± SD, n=4.  
(C) Immunoblotting for MIA PaCa-2 and Panc-1 cells treated for 24 hours as 
indicated. Ponceau S was used as loading control. Asterisk indicates that Panc-1 
lysates for the CHK1 S296 blot were from a 72-hour treatment. 
(D) Immunofluorescence for ATM S1981. MIA PaCa-2 cells were treated with either 
vehicle or 10nM gemcitabine+1uM S1181 for 24 hours. Scale bar, 20um. 
(E) Clonogenic assays. Cells were treated for 72 hours, re-plated in fresh medium 
and left to grow for 7 days. Data are represented as mean ± SEM, n=3. *p≤0.05, 
**p≤0.01, ***p≤0.001, ****p≤0.0001. 
Note to all figures: Where applicable, treatments were done at synergistic 
concentrations, i.e. HT-29 (1uM S1181/30nM gemcitabine), K8484 (1uM 
27 
 
S1181/10nM gemcitabine), MIA PaCa-2 (1uM S1181/10nM gemcitabine), Panc-1 
(3uM S1181/30nM gemcitabine).  
Figure 2. G2/M checkpoint abrogation does not portend effective synergy. 
(A) Quantification of immunoblots for Panc-1 cells treated as indicated. Data are 
normalized to control and are represented as mean ± SEM, n=3. **p≤0.01, 
***p≤0.001, ****p≤0.0001. 
(B) Quantification of DNA content of G1 and mitotic MIA PaCa-2 cells treated as 
indicated. Data are represented as mean ± SEM. G1 cells (n=250) and pHH3+ cells 
(n=30-50) were scored per sample. N denotes genetic content as quantified by DAPI 
staining. 
(C) Immunoblotting for Panc-1 cells treated as indicated. 
(D) Immunoblotting for K8484 cells treated as indicated. 
(E) 2D scatter diagrams for HT-29 cells treated as indicated. Propidium iodide was 
used as the surrogate for DNA content. Percentage of cells in the two upper 
quadrants is shown. 
(A-E) Treatments were done for 24 hours. Where applicable, synergistic 
concentrations were used (refer to Figure 1 legend) and were indicated in square 
brackets in Fig. B-D.  
Figure 3. S/G2 progression is a distinct predictor of cell fate. 
(A) Cell cycle profiles for MIA PaCa-2 cells treated for 24 hours as indicated. 
Synergistic concentrations were used, i.e. 10nM gemcitabine, 1uM S1181, 20nM 
CHIR-124. For quantification of S-phase population with S1181, see Supplementary 
Table S2. 
(B) S/G2 duration in MIA PaCa-2 Fucci cells treated as indicated and imaged by 
time-lapse microscopy as described in Supplementary Materials and Methods. S/G2 
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duration was defined as the interval between the time geminin (green fluorescence) 
was detected to the time of its disappearance. A total of 2191 cells were pooled from 
two biological replicates for analysis. Data are represented as mean ± SEM. 
****p≤0.0001. 
(C) Time-lapse sequences illustrating deleterious fates exhibited by MIA PaCa-2 
Fucci cells upon 10nM gemcitabine+1uM S1181 treatment. Scale bar, 50um. 
(D) Fate profiles of 115 individual MIA PaCa-2 Fucci cells from the point of 10nM 
gemcitabine+1uM S1181 treatment to the end of the first observed mitosis (if 
occurred). Solid bar denotes the duration of the specified phase of each 1st-
generation cell and is ranked according to S/G2 duration (green bar). Dotted bar 
denotes the outcome of the observed mitosis without further temporal reference. 
Truncated bar denotes cell elimination at that phase. 
(E) Fates of 150 daughter MIA PaCa-2 Fucci cells treated with 10nM 
gemcitabine+1uM S1181 (blue = successful cytokinesis, red = cytokinesis failure, 
black = death/senescence/interphase arrest) correlated with their maternal S/G2 and 
mitotic durations. Data are represented as mean ± SEM. The slope and p-value 
obtained from a linear regression analysis are shown. 
(F) Cross-generation S/G2 duration in MIA PaCa-2 Fucci cells treated with 10nM 
gemcitabine+1uM S1181. Cells that were initially at G1 (1st generation) that 
subsequently produced at least one dividing daughter (2nd generation) were tracked 
for their S/G2 durations. Blue marks cells with successful cytokinesis, red marks 
cells that failed to divide. Data are represented as mean ± SEM. A paired two-tailed 
t-test was used for significance, ****p≤0.0001.  
(D-F) Data were pooled from three biological replicates for analysis. 
Figure 4. Deregulated DNA replication causes synergistic growth inhibition. 
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(A) EdU incorporation. Double thymidine-synchronized MIA PaCa-2 cells were 
released into indicated treatment conditions labelled with 10uM EdU, fixed at 
specified intervals and assayed for EdU signal (Click-it reaction). Quantitative 
microscopy was performed to determine the total and maximal EdU intensities per 
nucleus for each of >3500 individual cells/sample. Percentages of positive cells 
(blue) are shown. 
(B) Immunofluorescence in cells treated for 24 hours as indicated. Quantitative 
microscopy was performed to determine the total fluorescence intensities per 
nucleus. Respectively, blue, yellow and red mark individual cells that were positive 
for yH2AX, for RPA32 S4/8 and for both markers. Percentages of double-positive 
cells are shown. 
(C) Cell cycle profiles of MIA PaCa-2 cells treated for 12 hours as indicated. Profile 
for gemcitabine+S1181 sample (gray) serves as background reference. 
(D) Immunofluorescence in Panc-1 cells treated for 24 hours as indicated. 
Quantitative microscopy was performed. Respective percentages of yH2AX only 
(blue), RPA32 S4/8 only (yellow) and yH2AX+RPA32 S4/8 positive (red) cells are 
shown. 
(E) Cell proliferation in K8484 cells treated as indicated. Three random fields of view 
per sample were imaged by time-lapse microscopy at every 3 hours. Data are 
represented as mean ± SEM, n=3. Area under the curve was used as the surrogate 
for growth over time. A two-tailed t-test was used for significance between 
GEM+S1181 and GEM+S1181+Roscovitine or GEM+S1181+Cdc7i from three 
independent experiments. *p≤0.05. 
(A-E) Treatments were done at synergistic concentrations (refer to Figure 1 legend). 
Roscovitine and Cdc7i were used at 10uM and 1uM, respectively.  
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Figure 5. Cumulative chromosomal aberrations are due to replication stress. 
(A) Mitotic aberrations in MIA PaCa-2 cells treated with gemcitabine+S1181. 
Arrowhead denotes lagging chromosomes (top) and anaphase bridge (bottom). 
Scale bar, 10um. 
(B) Quantification of mitotic aberrations in cells treated for 24 hours as indicated. 
>200 mitotic cells per condition on average were scored. Data are represented as 
mean ± SEM, n=3-5. *p≤0.05, **p≤0.01, ****p≤0.0001.  
(C) Stacked confocal images of misaligned metaphases of MIA PaCa-2 cells treated 
with gemcitabine+S1181 and stained as indicated. Scale bar, 10um. 
(D) Mitoses of MIA PaCa-2 cells treated with gemcitabine+S1181 and stained as 
indicated. Scale bar, 5um. 
(E) Stacked confocal image of aberrant HT-29 mitotic cell (arrowhead) treated with 
gemcitabine+S1181. EdU-positive cells were outlined with dotted line. Scale bar, 
10um. 
(F) Representative metaphase spreads of MIA PaCa-2 cells treated with 
gemcitabine+S1181 for 24-72 hours. Scale bar, 10um. 
(A-F) Treatments were done at synergistic concentrations (refer to Figure 1 legend).  
Figure 6. Molecular and cellular responses to treatment are concentration-
sensitive. 
(A) A generalized model on the modulation of mitotic CDK1 and mitotic states by 
gemcitabine and CHK1i. 
(B) A “foot-in-the-door” model of cell fates upon treatment with synergistic 
concentrations of gemcitabine and CHK1i.  
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